Ara-290: The EPO-Derived Peptide for Tissue Protection Research

Ara-290 (also known as cibinetide, helix B surface peptide/HBSP, or pyroglutamate-EELERALNSS) represents a breakthrough in tissue-protective peptide design—a synthetic 11-amino-acid fragment engineered from the tertiary structure of erythropoietin (EPO). Developed by Michael Brines and Anthony Cerami at Araim Pharmaceuticals, this peptide captures the tissue-protective properties of EPO while eliminating the hematopoietic effects that limit the hormone’s therapeutic utility. Ara-290 has advanced through clinical trials for diabetic neuropathy and sarcoidosis-associated small fiber neuropathy, demonstrating the potential of selective innate repair receptor activation.

The development of Ara-290 solved a fundamental problem in EPO therapeutics. While recombinant human EPO has remarkable tissue-protective properties—including anti-apoptotic, anti-inflammatory, and pro-repair effects—it also stimulates red blood cell production, raising hematocrit and increasing thrombotic risk. By identifying the specific structural domain responsible for tissue protection (helix B) and synthesizing it as an independent peptide, researchers created a molecule that retains therapeutic benefits without the problematic side effects.

Molecular Structure and Design

Ara-290 is a linear synthetic peptide of just 11 amino acids with the sequence QEQLERALNSS (pyroglutamate-Glu-Glu-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser). The N-terminal glutamine is modified to pyroglutamate, a cyclic derivative that enhances metabolic stability. With a molecular weight of approximately 1,257 daltons, Ara-290 is among the smallest biologically active peptides in clinical development.

The peptide was designed based on structural analysis of the EPO molecule, specifically the aqueous-exposed face of helix B. This region of EPO is not involved in binding the classical homodimeric EPO receptor (EPOR) that mediates erythropoiesis. Instead, helix B interacts with a distinct receptor complex—the innate repair receptor (IRR)—that becomes expressed specifically on stressed or injured tissues.

The engineering rationale was elegant: by isolating the helix B domain as an independent peptide, Ara-290 activates tissue-protective pathways without engaging erythropoietic signaling. This selectivity transforms a hormone with narrow therapeutic index into a peptide with potentially broad applications in tissue protection and repair.

Mechanism of Action: Innate Repair Receptor Activation

The biological effects of Ara-290 are mediated through the innate repair receptor (IRR), a heteromeric complex composed of the erythropoietin receptor (EPOR) and the beta-common receptor (CD131, also called betacR). This receptor complex has distinct properties from the classical EPOR homodimer:

Selective Expression: The IRR is not constitutively expressed on healthy cells. Instead, it becomes rapidly upregulated in response to tissue injury, hypoxia, inflammation, or metabolic stress. This injury-activated expression pattern means that Ara-290 preferentially affects damaged tissues while sparing healthy ones.

Anti-Apoptotic Signaling: When Ara-290 binds to the IRR, it initiates intracellular signaling cascades that inhibit programmed cell death. This includes activation of Akt, STAT5, and other survival pathways that protect cells from ischemic, inflammatory, or toxic insults.

Anti-Inflammatory Effects: IRR activation suppresses local pro-inflammatory cytokine production, reducing the inflammatory response that contributes to tissue damage. This immunomodulatory effect is particularly relevant for neuropathic conditions where inflammation drives pain and nerve degeneration.

Tissue Repair Promotion: Beyond protection, IRR signaling appears to actively promote repair processes, including angiogenesis, neurogenesis, and tissue remodeling. These regenerative effects may contribute to functional recovery in chronic conditions.

The net result is a peptide that can protect and repair multiple tissue types—including nerves, blood vessels, heart, kidney, and brain—without the hematologic effects that limit EPO use.

Clinical Research and Applications

Ara-290 has been most extensively studied in peripheral neuropathy, where small fiber nerve damage produces debilitating pain and sensory dysfunction. The clinical development program has focused on two primary indications:

Sarcoidosis-Associated Small Fiber Neuropathy: Phase 2 clinical trials in patients with sarcoidosis demonstrated that Ara-290 increased corneal nerve fiber density—a structural measure of small nerve fiber regeneration—and reduced neuropathic pain scores. These findings established proof-of-concept for nerve repair and earned Ara-290 FDA Orphan Drug designation for this indication.

Diabetic Neuropathy: Research published in Molecular Medicine showed that Ara-290 improved metabolic control and neuropathic symptoms in patients with type 2 diabetes. The peptide’s ability to address both metabolic dysfunction and nerve damage makes it particularly relevant for diabetic complications.

Additional Research Areas: Preclinical studies have explored Ara-290 in various tissue injury models including:

• Peripheral nerve injury: Functional recovery after sciatic nerve crush in rats
• Autoimmune neuritis: Inflammation suppression in experimental models
• Cardiac protection: Ischemia-reperfusion injury models
• Renal protection: Kidney injury and repair mechanisms
• Neurodegeneration: Potential applications in cognitive dysfunction

Research published in PLOS One demonstrated that Ara-290 ameliorates experimental autoimmune neuritis through inflammation suppression and tissue protection, providing mechanistic insights relevant to human neuropathic conditions.

Ara-290 vs. Erythropoietin

Understanding Ara-290’s value requires comparison with its parent molecule:

Recombinant Human EPO provides robust tissue protection but carries significant risks: hematocrit elevation, hypertension, thrombosis, and potential tumor promotion. These side effects limit dosing and duration, particularly in non-anemic patients who might benefit from tissue-protective effects.

Darbepoetin and Other EPO Analogs extend half-life but retain the same receptor-mediated side effects. They offer no selectivity advantage for tissue protection versus erythropoiesis.

Ara-290 achieves the desired separation—tissue protection without hematopoiesis—by targeting the IRR rather than the classical EPOR. This receptor selectivity enables safe administration to patients with normal hematocrit who need nerve or tissue protection.

The clinical safety profile of Ara-290 reflects this selectivity. Trials have not shown the hematologic side effects that limit EPO use, supporting the mechanistic rationale of IRR-selective agonism.

Pharmacokinetic Properties

Ara-290 presents an interesting pharmacokinetic profile. Despite its extremely short plasma half-life—approximately 2 minutes—the peptide produces sustained biological effects. This disconnect between plasma clearance and therapeutic duration suggests that Ara-290 acts through receptor-mediated events that persist beyond the peptide’s presence in circulation.

The brief half-life likely reflects rapid renal clearance given the small size (11 amino acids, ~1.3 kDa) and hydrophilic nature. However, once bound to the IRR on target tissues, the initiated signaling cascades—including gene expression changes and cellular adaptations—continue for hours to days.

This pharmacokinetic-pharmacodynamic disconnect has important implications for dosing. Clinical protocols have used subcutaneous administration with dosing intervals that account for sustained tissue effects rather than plasma concentrations.

Research Applications and Considerations

Laboratories working with Ara-290 have a unique tool for investigating tissue-protective mechanisms and the innate repair receptor pathway. Research applications include:

• Neuropathy models: Studying nerve regeneration and pain mechanisms in diabetic or toxic neuropathy
• Ischemia-reperfusion: Cardiac, cerebral, and renal ischemia models
• Inflammation research: Mechanisms of cytokine suppression and immune modulation
• Receptor pharmacology: Characterizing IRR signaling and selectivity versus EPOR
• Combination studies: Interactions with other neuroprotective or tissue-protective agents

Standard reconstitution uses bacteriostatic water or sterile saline, with storage of lyophilized powder under refrigeration. The small size and linear structure make Ara-290 relatively straightforward to handle compared to larger, more complex peptides.

As with all research peptides, Ara-290 is intended strictly for laboratory investigation and is not approved for human use outside of clinical trials.

Current Development Status

As of 2026, Ara-290 has completed Phase 2 clinical trials with promising results but has not yet advanced to Phase 3 or received regulatory approval. The positive data in sarcoidosis neuropathy and diabetic neuropathy support continued development, though the path to commercialization remains uncertain.

The peptide holds FDA Orphan Drug designation for sarcoidosis-associated small fiber neuropathy, which provides incentives for development of treatments for rare diseases. This designation reflects the unmet medical need and the promising early clinical data.

For research laboratories, Ara-290 represents a clinically validated tool for investigating tissue-protective mechanisms. The extensive human safety data from clinical trials, combined with the compelling efficacy signals, make it an attractive compound for mechanistic studies.

Explore our comprehensive selection of research peptides and neuroprotective compounds for your laboratory studies. Visit our homepage to discover the latest additions to our research catalog.

References

• “ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes.” Molecular Medicine, Springer. https://link.springer.com/article/10.2119/molmed.2014.00215
• “Erythropoietin-Derived Nonerythropoietic Peptide Ameliorates Experimental Autoimmune Neuritis by Inflammation Suppression and Tissue Protection.” PLOS One. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0090942
• “The protective effect of erythropoietin and its novel derived peptides in peripheral nerve injury.” ScienceDirect. https://www.sciencedirect.com/science/article/abs/pii/S1567576924009731
• “ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception.” ScienceDirect. https://www.sciencedirect.com/science/article/abs/pii/S0196978116300031
• “Cibinetide.” Wikipedia. https://en.wikipedia.org/wiki/Cibinetide

Disclaimer: This product is sold for laboratory research purposes only. Ara-290 is not intended for human consumption, medical treatment, or diagnostic use. It is an investigational compound that has not received regulatory approval. This information is provided for educational purposes and does not constitute medical or scientific advice. Always consult relevant scientific literature and follow proper laboratory safety protocols.